154 related articles for article (PubMed ID: 34339273)
1. Associations between Varied Susceptibilities to PfATP4 Inhibitors and Genotypes in Ugandan Plasmodium falciparum Isolates.
Kreutzfeld O; Rasmussen SA; Ramanathan AA; Tumwebaze PK; Byaruhanga O; Katairo T; Asua V; Okitwi M; Orena S; Legac J; Conrad MD; Nsobya SL; Aydemir O; Bailey J; Duffey M; Bayles BR; Vaidya AB; Cooper RA; Rosenthal PJ
Antimicrob Agents Chemother; 2021 Sep; 65(10):e0077121. PubMed ID: 34339273
[TBL] [Abstract][Full Text] [Related]
2. Susceptibility of Ugandan Plasmodium falciparum Isolates to the Antimalarial Drug Pipeline.
Kreutzfeld O; Tumwebaze PK; Okitwi M; Orena S; Byaruhanga O; Katairo T; Conrad MD; Rasmussen SA; Legac J; Aydemir O; Giesbrecht D; Forte B; Campbell P; Smith A; Kano H; Nsobya SL; Blasco B; Duffey M; Bailey JA; Cooper RA; Rosenthal PJ
Microbiol Spectr; 2023 Jun; 11(3):e0523622. PubMed ID: 37158739
[TBL] [Abstract][Full Text] [Related]
3. Decreased Susceptibility to Dihydrofolate Reductase Inhibitors Associated With Genetic Polymorphisms in Ugandan Plasmodium falciparum Isolates.
Kreutzfeld O; Tumwebaze PK; Byaruhanga O; Katairo T; Okitwi M; Orena S; Rasmussen SA; Legac J; Conrad MD; Nsobya SL; Aydemir O; Bailey JA; Duffey M; Cooper RA; Rosenthal PJ
J Infect Dis; 2022 Feb; 225(4):696-704. PubMed ID: 34460932
[TBL] [Abstract][Full Text] [Related]
4. Biochemical characterization and chemical inhibition of PfATP4-associated Na
Rosling JEO; Ridgway MC; Summers RL; Kirk K; Lehane AM
J Biol Chem; 2018 Aug; 293(34):13327-13337. PubMed ID: 29986883
[TBL] [Abstract][Full Text] [Related]
5. A G358S mutation in the Plasmodium falciparum Na
Qiu D; Pei JV; Rosling JEO; Thathy V; Li D; Xue Y; Tanner JD; Penington JS; Aw YTV; Aw JYH; Xu G; Tripathi AK; Gnadig NF; Yeo T; Fairhurst KJ; Stokes BH; Murithi JM; Kümpornsin K; Hasemer H; Dennis ASM; Ridgway MC; Schmitt EK; Straimer J; Papenfuss AT; Lee MCS; Corry B; Sinnis P; Fidock DA; van Dooren GG; Kirk K; Lehane AM
Nat Commun; 2022 Sep; 13(1):5746. PubMed ID: 36180431
[TBL] [Abstract][Full Text] [Related]
6. Susceptibilities of Ugandan Plasmodium falciparum Isolates to Proteasome Inhibitors.
Garg S; Kreutzfeld O; Chelebieva S; Tumwebaze PK; Byaruhanga O; Okitwi M; Orena S; Katairo T; Nsobya SL; Conrad MD; Aydemir O; Legac J; Gould AE; Bayles BR; Bailey JA; Duffey M; Lin G; Kirkman LA; Cooper RA; Rosenthal PJ
Antimicrob Agents Chemother; 2022 Oct; 66(10):e0081722. PubMed ID: 36094216
[TBL] [Abstract][Full Text] [Related]
7. Cation ATPase (ATP4) Orthologue Replacement in the Malaria Parasite Plasmodium knowlesi Reveals Species-Specific Responses to ATP4-Targeting Drugs.
Mohring F; van Schalkwyk DA; Henrici RC; Blasco B; Leroy D; Sutherland CJ; Moon RW
mBio; 2022 Oct; 13(5):e0117822. PubMed ID: 36190127
[TBL] [Abstract][Full Text] [Related]
8. Drug susceptibility of
Tumwebaze PK; Katairo T; Okitwi M; Byaruhanga O; Orena S; Asua V; Duvalsaint M; Legac J; Chelebieva S; Ceja FG; Rasmussen SA; Conrad MD; Nsobya SL; Aydemir O; Bailey JA; Bayles BR; Rosenthal PJ; Cooper RA
Lancet Microbe; 2021 Sep; 2(9):e441-e449. PubMed ID: 34553183
[TBL] [Abstract][Full Text] [Related]
9. The malaria parasite cation ATPase PfATP4 and its role in the mechanism of action of a new arsenal of antimalarial drugs.
Spillman NJ; Kirk K
Int J Parasitol Drugs Drug Resist; 2015 Dec; 5(3):149-62. PubMed ID: 26401486
[TBL] [Abstract][Full Text] [Related]
10. Impact of Short-Term Storage on
Okitwi M; Orena S; Thomas K; Tumwebaze PK; Byaruhanga O; Nsobya SL; Conrad MD; Bayles BR; Rosenthal PJ; Cooper RA
Antimicrob Agents Chemother; 2022 Apr; 66(4):e0143721. PubMed ID: 35266828
[TBL] [Abstract][Full Text] [Related]
11. Decreased susceptibility of Plasmodium falciparum to both dihydroartemisinin and lumefantrine in northern Uganda.
Tumwebaze PK; Conrad MD; Okitwi M; Orena S; Byaruhanga O; Katairo T; Legac J; Garg S; Giesbrecht D; Smith SR; Ceja FG; Nsobya SL; Bailey JA; Cooper RA; Rosenthal PJ
Nat Commun; 2022 Oct; 13(1):6353. PubMed ID: 36289202
[TBL] [Abstract][Full Text] [Related]
12. Cell Swelling Induced by the Antimalarial KAE609 (Cipargamin) and Other PfATP4-Associated Antimalarials.
Dennis ASM; Lehane AM; Ridgway MC; Holleran JP; Kirk K
Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29555632
[TBL] [Abstract][Full Text] [Related]
13. Changing Antimalarial Drug Sensitivities in Uganda.
Rasmussen SA; Ceja FG; Conrad MD; Tumwebaze PK; Byaruhanga O; Katairo T; Nsobya SL; Rosenthal PJ; Cooper RA
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923866
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of mutations in the Plasmodium falciparum chloroquine resistance transporter, PfCRT, and association with ex vivo susceptibility to common anti-malarial drugs against African Plasmodium falciparum isolates.
Foguim FT; Bogreau H; Gendrot M; Mosnier J; Fonta I; Benoit N; Amalvict R; Madamet M; Wein S; Pradines B;
Malar J; 2020 Jun; 19(1):201. PubMed ID: 32503540
[TBL] [Abstract][Full Text] [Related]
15. Molecular surveillance of Plasmodium falciparum drug resistance markers reveals partial recovery of chloroquine susceptibility but sustained sulfadoxine-pyrimethamine resistance at two sites of different malaria transmission intensities in Rwanda.
Kateera F; Nsobya SL; Tukwasibwe S; Hakizimana E; Mutesa L; Mens PF; Grobusch MP; van Vugt M; Kumar N
Acta Trop; 2016 Dec; 164():329-336. PubMed ID: 27647575
[TBL] [Abstract][Full Text] [Related]
16. Metabolic responses in blood-stage malaria parasites associated with increased and decreased sensitivity to PfATP4 inhibitors.
Tewari SG; Elahi R; Kwan B; Rajaram K; Bhatnagar S; Reifman J; Prigge ST; Vaidya AB; Wallqvist A
Malar J; 2023 Feb; 22(1):56. PubMed ID: 36788578
[TBL] [Abstract][Full Text] [Related]
17. Antimalarials Targeting the Malaria Parasite Cation ATPase
Zagórska A; Jaromin A
Curr Top Med Chem; 2023; 23(3):214-226. PubMed ID: 36411573
[TBL] [Abstract][Full Text] [Related]
18. Treatment Failure in a UK Malaria Patient Harboring Genetically Variant Plasmodium falciparum From Uganda With Reduced In Vitro Susceptibility to Artemisinin and Lumefantrine.
van Schalkwyk DA; Pratt S; Nolder D; Stewart LB; Liddy H; Muwanguzi-Karugaba J; Beshir KB; Britten D; Victory E; Rogers C; Millard J; Brown M; Nabarro LE; Taylor A; Young BC; Chiodini PL; Sutherland CJ
Clin Infect Dis; 2024 Feb; 78(2):445-452. PubMed ID: 38019958
[TBL] [Abstract][Full Text] [Related]
19. (+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium.
Jiménez-Díaz MB; Ebert D; Salinas Y; Pradhan A; Lehane AM; Myrand-Lapierre ME; O'Loughlin KG; Shackleford DM; Justino de Almeida M; Carrillo AK; Clark JA; Dennis AS; Diep J; Deng X; Duffy S; Endsley AN; Fedewa G; Guiguemde WA; Gómez MG; Holbrook G; Horst J; Kim CC; Liu J; Lee MC; Matheny A; Martínez MS; Miller G; Rodríguez-Alejandre A; Sanz L; Sigal M; Spillman NJ; Stein PD; Wang Z; Zhu F; Waterson D; Knapp S; Shelat A; Avery VM; Fidock DA; Gamo FJ; Charman SA; Mirsalis JC; Ma H; Ferrer S; Kirk K; Angulo-Barturen I; Kyle DE; DeRisi JL; Floyd DM; Guy RK
Proc Natl Acad Sci U S A; 2014 Dec; 111(50):E5455-62. PubMed ID: 25453091
[TBL] [Abstract][Full Text] [Related]
20. Correlation of in vivo-resistance to chloroquine and allelic polymorphisms in Plasmodium falciparum isolates from Uganda.
Flüeck TP; Jelinek T; Kilian AH; Adagu IS; Kabagambe G; Sonnenburg F; Warhurst DC
Trop Med Int Health; 2000 Mar; 5(3):174-8. PubMed ID: 10747279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
